• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

Chacruna Publishes Article Challenging DEA Ayahuasca Report

Microdose NewsDesk by Microdose NewsDesk
June 15, 2023
in Industry
Reading Time: 2 mins read
A A
Chacruna Publishes Article Challenging DEA Ayahuasca Report

 

 

Chacruna Publishes Article Challenging DEA Ayahuasca Report

 

Chacruna Institute

Chacruna Institute

[bsa_pro_ad_space id=2]
ADVERTISEMENT

In February 2023, the Drug Enforcement Administration (DEA) released a document to the legal team representing the Church of the Eagle and the Condor (CEC). This disclosure came two years after the CEC and the Chacruna Institute for Psychedelic Plant Medicines submitted two FOIA requests to the DEA and the Department of Justice requesting all records pertaining to ayahuasca.

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

The report, titled “Ayahuasca: Risks to Public Health and Safety,” was issued in July 2020. It takes a very clear stance against the use of ayahuasca, claiming that it presents a significant risk to public health and safety. The report is in line with the prohibitionist approach of the US government, which has continued to target ayahuasca groups through seizures, arrests and other actions. The report is also a strong indication that the government will be resistant to recognizing religious minorities and traditional populations’ rights.

On June 9, 2023, the Chacruna Institute published an article in the peer-reviewed Journal of Psychedelic Studies contesting the DEA’s report. The article, “The DEA Report on Ayahuasca Risks: ‘Science’ in Service of Prohibition?

Save on Lasix Online

” was written in partnership with leading experts on ayahuasca, including scholars from the fields of biology, neuroscience, psychology, psychiatry, anthropology, and sociology.

THIS ARTICLE SHOWS THAT THE PROHIBITIONIST PARADIGM AND THE PERSECUTION OF ETHNIC AND RELIGIOUS MINORITIES WILL NOT BE IGNORED AND THAT THE GLOBAL SCIENTIFIC COMMUNITY IS TAKING A STAND AGAINST THE CRIMINALIZATION OF AYAHUASCA.

The article challenges a number of assertions made by the DEA, highlighting significant factual omissions, theoretical biases, and misinterpretations of existing data. The article highlights how the DEA report severely downplays the safety profile and therapeutic potential of ayahuasca, ignores a vast body of epidemiological evidence from its use among Indigenous and religious communities around the world, and overemphasizes the risks, while failing to include current research on ayahuasca demonstrating its potential benefits.

This shows that the prohibitionist paradigm and the persecution of ethnic and religious minorities will not be ignored and that the global scientific community is taking a stand against the criminalization of ayahuasca. If you want to read the full critique of the DEA’s report, click the button. To support this kind of critical psychedelic scholarship, please consider donating to support Chacruna’s mission.

Read the Full Article

Donate to Chacruna

[bsa_pro_ad_space id=2]
ADVERTISEMENT
Tags: chacruna
Microdose NewsDesk

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Next Post
Republican Lawmakers Introduce New Bill for Psychedelic Therapy

Republican Lawmakers Introduce New Bill for Psychedelic Therapy

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.